

---

**From:** Kincaide, Johnny <Johnny.Kincaide@andanet.com>  
**Sent:** Friday, November 03, 2017 8:34 PM  
**To:** Spellman, Jay; Schultz, Emily  
**Subject:** FW: Questions regarding compliance decisions

**Importance:** High

I called and spoke with David Lemoine on Tuesday, October 31<sup>st</sup>. The agent stated that they received a list of customers not eligible to purchase controls from Anda in 2015 from Robert Brown. The list contained a number of pharmacies located in Louisiana that were no longer eligible to purchase controlled substances from Anda. He said the purpose of the request was to gain some understanding of the factors we considered to be important in making the determinations to cut off controls or report certain accounts. He reiterated several times that we had done nothing wrong and that in fact we had done everything right. He asked for some detail on our review process, specifically what we deemed important when reviewing responses to supplemental information requests and updated dispense data.

I gave him a general overview of our SOPs for new account and limits reviews. I said we consider many factors including controls ratios, pill and prescription quantities in the provided data, prescriber information, geographic trends and their historic sales trends with Anda.

He also asked whether our decisions were the result of fixed internal ratios (controls to non-controls)/thresholds set by our department and whether we have access to outside sources of information regarding our customer's dispensing habits. I told him we rely on our own analysis and that each account is reviewed on its own merit.

**John Kincaide**

Regulatory Compliance, Anda, Inc.

TF: 800.331.2632 Ext. 74599

F: 954.217.4479

E: [Johnny.Kincaide@andanet.com](mailto:Johnny.Kincaide@andanet.com)

2915 Weston Road, Weston, FL 33331



---

**From:** Gatto, James  
**Sent:** Tuesday, October 31, 2017 4:25 PM  
**To:** Schultz, Emily  
**Cc:** Spellman, Jay; Kincaide, Johnny  
**Subject:** FW: Questions regarding compliance decisions  
**Importance:** High

**James C Gatto**

DEA Compliance Specialist | Anda, Inc.

2915 Weston Road  
Weston, FL 33331

P 1-800-331-ANDA (2632) Ext. 54240

F 1-855-810-6986



---

**From:** Lemoine, David A. [<mailto:David.A.Lemoine@usdoj.gov>]  
**Sent:** Tuesday, October 31, 2017 3:56 PM  
**To:** Gatto, James  
**Subject:** Questions regarding compliance decisions

Mr. Gatto,

As per our conversation earlier today, in September 2015, we received an updated list of customers not eligible to purchase controls from Anda.

In reviewing your updated list, we identified a number of pharmacies located in Louisiana that are no longer eligible to purchase controlled substances from Anda. The email included with the list stated that the determinations were not based on Suspicious Orders, but rather, "receipt and review of additional information, including updated dispense data."

We would like to determine if these determinations were the result of internal thresholds established by your firm, or if you were able to access other sources of data that provide you with information regarding your customer's dispensing habits.

We are in the process of reviewing different elements that are considered during our audits which are conducted at retail pharmacies in every state. We are also concentrating our efforts on the dispensing data related to each pharmacy, so that unusual trends can be identified in a more efficient manner.

Please contact me, at your convenience, so that we can discuss this information in more detail.

Thank you,

**David A. Lemoine**  
Diversion Investigator  
Drug Enforcement Administration  
New Orleans Field Division  
Office: 504-840-1069  
[www.deadiversion.usdoj.gov](http://www.deadiversion.usdoj.gov)

